Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke

Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of stroke and cerebrovascular diseases 2016-05, Vol.25 (5), p.1035-1040
Hauptverfasser: Momosaki, Ryo, MD, PhD, MPH, Yasunaga, Hideo, MD, PhD, Matsui, Hiroki, PT, MPH, Fushimi, Kiyohide, MD, PhD, Abo, Masahiro, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1040
container_issue 5
container_start_page 1035
container_title Journal of stroke and cerebrovascular diseases
container_volume 25
creator Momosaki, Ryo, MD, PhD, MPH
Yasunaga, Hideo, MD, PhD
Matsui, Hiroki, PT, MPH
Fushimi, Kiyohide, MD, PhD
Abo, Masahiro, MD, PhD
description Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke.
doi_str_mv 10.1016/j.jstrokecerebrovasdis.2016.01.018
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1783915069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1052305716000318</els_id><sourcerecordid>1783915069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</originalsourceid><addsrcrecordid>eNqVklGL1DAUhYso7rr6FySPInRM0qZNX4RxWd2FAYddfQ5pcuum0yZjbjqy_96Ms_ogvggXEnIP59x83KJ4y-iKUda8G1cjphh2YCBCH8NBo3W44rm3oiyXfFKcM1HxUgrGnuY7FbysqGjPiheII6WMCSmeF2e8kaJiNT8v4jaGFDzZLvOe3Ph717sUIpIDRFyQXDtMenYeSk5uc-4-N8naJ_0t-NxCor0ltw53JAxk62GZ87smLhvq5MBnxQ-X7snaLAnI3a_pXxbPBj0hvHo8L4qvH6--XF6Xm8-fbi7Xm9LUokulNU3baNCMdpUFaTk0Q625YaKnUlZtO_BaCqGHru6sFo2phr7jRgyttD3XdXVRvDn57mP4vgAmNTs0ME3aQ1hQsVZWHRO06bL0w0lqYkCMMKh9dLOOD4pRdWSvRvUv9urIXlGWS2aT1495Sz-D_WPxG3YWbE4CyL8-OIgKTWZkwLoIJikb3P_lvf_LzkzOO6OnHTwAjmGJPvNVTCFXVN0dt-G4DKyhlFbZ4CfgB7qD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1783915069</pqid></control><display><type>article</type><title>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Momosaki, Ryo, MD, PhD, MPH ; Yasunaga, Hideo, MD, PhD ; Matsui, Hiroki, PT, MPH ; Fushimi, Kiyohide, MD, PhD ; Abo, Masahiro, MD, PhD</creator><creatorcontrib>Momosaki, Ryo, MD, PhD, MPH ; Yasunaga, Hideo, MD, PhD ; Matsui, Hiroki, PT, MPH ; Fushimi, Kiyohide, MD, PhD ; Abo, Masahiro, MD, PhD</creatorcontrib><description>Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke.</description><identifier>ISSN: 1052-3057</identifier><identifier>EISSN: 1532-8511</identifier><identifier>DOI: 10.1016/j.jstrokecerebrovasdis.2016.01.018</identifier><identifier>PMID: 26853142</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>acute stroke ; Aged ; Aged, 80 and over ; Cardiovascular ; Chi-Square Distribution ; Comorbidity ; Databases, Factual ; Disability Evaluation ; Female ; Histamine H2 Antagonists - adverse effects ; histamine-2 receptor antagonists ; Humans ; Incidence ; Japan - epidemiology ; Logistic Models ; Male ; Middle Aged ; Neurology ; Pneumonia ; Pneumonia - diagnosis ; Pneumonia - epidemiology ; Propensity Score ; proton pump inhibitors ; Proton Pump Inhibitors - adverse effects ; Retrospective Studies ; Risk Factors ; Stroke - complications ; Stroke - diagnosis ; Stroke - epidemiology ; Stroke - therapy</subject><ispartof>Journal of stroke and cerebrovascular diseases, 2016-05, Vol.25 (5), p.1035-1040</ispartof><rights>National Stroke Association</rights><rights>2016 National Stroke Association</rights><rights>Copyright © 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</citedby><cites>FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</cites><orcidid>0000-0003-3274-3952</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1052305716000318$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26853142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Momosaki, Ryo, MD, PhD, MPH</creatorcontrib><creatorcontrib>Yasunaga, Hideo, MD, PhD</creatorcontrib><creatorcontrib>Matsui, Hiroki, PT, MPH</creatorcontrib><creatorcontrib>Fushimi, Kiyohide, MD, PhD</creatorcontrib><creatorcontrib>Abo, Masahiro, MD, PhD</creatorcontrib><title>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</title><title>Journal of stroke and cerebrovascular diseases</title><addtitle>J Stroke Cerebrovasc Dis</addtitle><description>Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke.</description><subject>acute stroke</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cardiovascular</subject><subject>Chi-Square Distribution</subject><subject>Comorbidity</subject><subject>Databases, Factual</subject><subject>Disability Evaluation</subject><subject>Female</subject><subject>Histamine H2 Antagonists - adverse effects</subject><subject>histamine-2 receptor antagonists</subject><subject>Humans</subject><subject>Incidence</subject><subject>Japan - epidemiology</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Pneumonia</subject><subject>Pneumonia - diagnosis</subject><subject>Pneumonia - epidemiology</subject><subject>Propensity Score</subject><subject>proton pump inhibitors</subject><subject>Proton Pump Inhibitors - adverse effects</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Stroke - complications</subject><subject>Stroke - diagnosis</subject><subject>Stroke - epidemiology</subject><subject>Stroke - therapy</subject><issn>1052-3057</issn><issn>1532-8511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVklGL1DAUhYso7rr6FySPInRM0qZNX4RxWd2FAYddfQ5pcuum0yZjbjqy_96Ms_ogvggXEnIP59x83KJ4y-iKUda8G1cjphh2YCBCH8NBo3W44rm3oiyXfFKcM1HxUgrGnuY7FbysqGjPiheII6WMCSmeF2e8kaJiNT8v4jaGFDzZLvOe3Ph717sUIpIDRFyQXDtMenYeSk5uc-4-N8naJ_0t-NxCor0ltw53JAxk62GZ87smLhvq5MBnxQ-X7snaLAnI3a_pXxbPBj0hvHo8L4qvH6--XF6Xm8-fbi7Xm9LUokulNU3baNCMdpUFaTk0Q625YaKnUlZtO_BaCqGHru6sFo2phr7jRgyttD3XdXVRvDn57mP4vgAmNTs0ME3aQ1hQsVZWHRO06bL0w0lqYkCMMKh9dLOOD4pRdWSvRvUv9urIXlGWS2aT1495Sz-D_WPxG3YWbE4CyL8-OIgKTWZkwLoIJikb3P_lvf_LzkzOO6OnHTwAjmGJPvNVTCFXVN0dt-G4DKyhlFbZ4CfgB7qD</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Momosaki, Ryo, MD, PhD, MPH</creator><creator>Yasunaga, Hideo, MD, PhD</creator><creator>Matsui, Hiroki, PT, MPH</creator><creator>Fushimi, Kiyohide, MD, PhD</creator><creator>Abo, Masahiro, MD, PhD</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3274-3952</orcidid></search><sort><creationdate>20160501</creationdate><title>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</title><author>Momosaki, Ryo, MD, PhD, MPH ; Yasunaga, Hideo, MD, PhD ; Matsui, Hiroki, PT, MPH ; Fushimi, Kiyohide, MD, PhD ; Abo, Masahiro, MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-dc676aea1093de8d2e6f4a2c15b088377f24855af949da56c3fb92c5f78db2a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>acute stroke</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cardiovascular</topic><topic>Chi-Square Distribution</topic><topic>Comorbidity</topic><topic>Databases, Factual</topic><topic>Disability Evaluation</topic><topic>Female</topic><topic>Histamine H2 Antagonists - adverse effects</topic><topic>histamine-2 receptor antagonists</topic><topic>Humans</topic><topic>Incidence</topic><topic>Japan - epidemiology</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Pneumonia</topic><topic>Pneumonia - diagnosis</topic><topic>Pneumonia - epidemiology</topic><topic>Propensity Score</topic><topic>proton pump inhibitors</topic><topic>Proton Pump Inhibitors - adverse effects</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Stroke - complications</topic><topic>Stroke - diagnosis</topic><topic>Stroke - epidemiology</topic><topic>Stroke - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Momosaki, Ryo, MD, PhD, MPH</creatorcontrib><creatorcontrib>Yasunaga, Hideo, MD, PhD</creatorcontrib><creatorcontrib>Matsui, Hiroki, PT, MPH</creatorcontrib><creatorcontrib>Fushimi, Kiyohide, MD, PhD</creatorcontrib><creatorcontrib>Abo, Masahiro, MD, PhD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of stroke and cerebrovascular diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Momosaki, Ryo, MD, PhD, MPH</au><au>Yasunaga, Hideo, MD, PhD</au><au>Matsui, Hiroki, PT, MPH</au><au>Fushimi, Kiyohide, MD, PhD</au><au>Abo, Masahiro, MD, PhD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke</atitle><jtitle>Journal of stroke and cerebrovascular diseases</jtitle><addtitle>J Stroke Cerebrovasc Dis</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>25</volume><issue>5</issue><spage>1035</spage><epage>1040</epage><pages>1035-1040</pages><issn>1052-3057</issn><eissn>1532-8511</eissn><abstract>Background Pneumonia is a serious complication of stroke. Several studies have indicated that certain gastric acid suppressants may be associated with an increased risk of pneumonia in hospitalized patients. However, the association between type of acid suppressant and pneumonia in acute stroke patients remains controversial. The purpose of this study was to clarify the association between the type of acid suppressant and the occurrence of pneumonia in acute stroke patients. Methods This retrospective observational study used data from the national Japanese Diagnosis Procedure Combination inpatient database. We identified patients who were admitted to acute-care hospitals with stroke. The outcome was the occurrence of pneumonia assessed using diagnostic codes. We performed propensity score-matched analysis to compare the outcome between proton pump inhibitor (PPI) users and histamine-2 receptor antagonist (H2RA) users. Results A total of 77,890 stroke patients were identified, of whom 63,980 were prescribed H2RAs and 13,910 were prescribed PPIs. Overall, 1490 (10.7%) of the patients receiving PPIs and 6401 (10.0%) of the patients receiving H2RAs developed pneumonia after stroke. After propensity score matching, the incidence of pneumonia in PPI users was not different from that in H2RA users (odds ratio: 1.10, 95% confidence interval: .99-1.21). Conclusion No significant difference in the incidence of pneumonia was seen between users of PPIs and H2RAs after acute stroke.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26853142</pmid><doi>10.1016/j.jstrokecerebrovasdis.2016.01.018</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3274-3952</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1052-3057
ispartof Journal of stroke and cerebrovascular diseases, 2016-05, Vol.25 (5), p.1035-1040
issn 1052-3057
1532-8511
language eng
recordid cdi_proquest_miscellaneous_1783915069
source MEDLINE; Elsevier ScienceDirect Journals
subjects acute stroke
Aged
Aged, 80 and over
Cardiovascular
Chi-Square Distribution
Comorbidity
Databases, Factual
Disability Evaluation
Female
Histamine H2 Antagonists - adverse effects
histamine-2 receptor antagonists
Humans
Incidence
Japan - epidemiology
Logistic Models
Male
Middle Aged
Neurology
Pneumonia
Pneumonia - diagnosis
Pneumonia - epidemiology
Propensity Score
proton pump inhibitors
Proton Pump Inhibitors - adverse effects
Retrospective Studies
Risk Factors
Stroke - complications
Stroke - diagnosis
Stroke - epidemiology
Stroke - therapy
title Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T14%3A36%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proton%20Pump%20Inhibitors%20versus%20Histamine-2%20Receptor%20Antagonists%20and%20Risk%20of%20Pneumonia%20in%20Patients%20with%20Acute%20Stroke&rft.jtitle=Journal%20of%20stroke%20and%20cerebrovascular%20diseases&rft.au=Momosaki,%20Ryo,%20MD,%20PhD,%20MPH&rft.date=2016-05-01&rft.volume=25&rft.issue=5&rft.spage=1035&rft.epage=1040&rft.pages=1035-1040&rft.issn=1052-3057&rft.eissn=1532-8511&rft_id=info:doi/10.1016/j.jstrokecerebrovasdis.2016.01.018&rft_dat=%3Cproquest_cross%3E1783915069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1783915069&rft_id=info:pmid/26853142&rft_els_id=1_s2_0_S1052305716000318&rfr_iscdi=true